WO1998021314A3 - Method of promoting B-cell proliferation and activation and of modulating the immune system - Google Patents

Method of promoting B-cell proliferation and activation and of modulating the immune system Download PDF

Info

Publication number
WO1998021314A3
WO1998021314A3 PCT/US1997/021858 US9721858W WO9821314A3 WO 1998021314 A3 WO1998021314 A3 WO 1998021314A3 US 9721858 W US9721858 W US 9721858W WO 9821314 A3 WO9821314 A3 WO 9821314A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
modulating
promoting
activation
cell proliferation
Prior art date
Application number
PCT/US1997/021858
Other languages
French (fr)
Other versions
WO1998021314A2 (en
Inventor
Joachim L Schultze
Gordon J Freeman
John G Gribben
Lee M Nadler
Original Assignee
Joachim L Schultze
Gordon J Freeman
John G Gribben
Lee M Nadler
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/748,341 external-priority patent/US6465251B1/en
Application filed by Joachim L Schultze, Gordon J Freeman, John G Gribben, Lee M Nadler, Dana Farber Cancer Inst Inc filed Critical Joachim L Schultze
Priority to AU55901/98A priority Critical patent/AU5590198A/en
Publication of WO1998021314A2 publication Critical patent/WO1998021314A2/en
Publication of WO1998021314A3 publication Critical patent/WO1998021314A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4612—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

We teach a strategy to obtain large quantities of desired APCs, activated B cells, which are superior in their capacity to present tumor protein antigen in a multiadministration protocol. Human B cells can be obtained from peripheral blood in large numbers. These cells can be activated in vitro by coculture with CD40L (CD40-B cells) and an immunosuppressive agent such as cyclosporin A. They can be expanded up to 1 x 103 to 1 x 104 fold in 2 weeks or 1 x 105 to 1 x 106 fold in 2 months. We demonstrate these cells are most efficient APCs comparable to DCs in stimulating allogeneic CD4?+ CD45RA+, CD4+¿, CD45RO+, and CD8+ T cells. In contrast to DCs, CD40-B cells are fully functional even in the presence of immunosuppressive cytokines such as IL-1O and TGFβ.
PCT/US1997/021858 1996-11-12 1997-11-12 Method of promoting b-cell proliferation and activation and of modulating the immune system WO1998021314A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU55901/98A AU5590198A (en) 1996-11-12 1997-11-12 Method of promoting b-cell proliferation and activation and of modulating the immune system

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3052796P 1996-11-12 1996-11-12
US60/030,527 1996-11-12
US08/748,341 1996-11-13
US08/748,341 US6465251B1 (en) 1996-11-13 1996-11-13 Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin

Publications (2)

Publication Number Publication Date
WO1998021314A2 WO1998021314A2 (en) 1998-05-22
WO1998021314A3 true WO1998021314A3 (en) 1998-10-01

Family

ID=26706140

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/021858 WO1998021314A2 (en) 1996-11-12 1997-11-12 Method of promoting b-cell proliferation and activation and of modulating the immune system

Country Status (2)

Country Link
AU (1) AU5590198A (en)
WO (1) WO1998021314A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9528088B2 (en) 2002-06-28 2016-12-27 Life Technologies Corporation Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2789089A1 (en) * 1999-02-02 2000-08-04 Pf Medicament HUMAN EFFECTOR T CELL LYMPHOCYTES EXPRESSING THE CD86 MOLECULE AND HAVING IMMUNODULATORY, COSTIMULATORY AND CYTOTOXIC PROPERTIES, METHODS OF OBTAINING THEM AND THEIR APPLICATIONS
EP2342350A4 (en) * 2008-09-23 2012-05-30 Hema Quebec Method for polyclonal immunoglobulin g production by human b cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029935A1 (en) * 1994-04-28 1995-11-09 Boehringer Ingelheim Pharmaceuticals, Inc. Method for proliferating and differentiating b cells, and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029935A1 (en) * 1994-04-28 1995-11-09 Boehringer Ingelheim Pharmaceuticals, Inc. Method for proliferating and differentiating b cells, and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J. BANCHEREAU ET AL.: "Growing human B lymphocytes in the CD40 system.", NATURE, vol. 353, no. 6345, 17 October 1991 (1991-10-17), LONDON, GB, pages 678 - 679, XP002071708 *
J. BANCHEREAU ET AL.: "Long-term human B cell lines dependent on interleukin-4 and antibody to CD40.", SCIENCE, vol. 251, no. 4989, 4 January 1991 (1991-01-04), WASHINGTON, DC, USA, pages 70 - 72, XP002071707 *
J. SCHULTZE ET AL.: "Advantages of human CD40 activated B cells over dendritic cells for presentation of human tumor antigens.", BLOOD, vol. 88, no. 10 suppl. 1 part 1-2, 6 December 1996 (1996-12-06) - 10 December 1996 (1996-12-10), NEW YORK, NY, USA, pages 162A, XP002071709 *
J. SCHULTZE ET AL.: "CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.", JOURNAL OF CLINICAL INVESTIGATION, vol. 100, no. 11, 1 December 1997 (1997-12-01), NEW YORK, NY, USA, pages 2757 - 2565, XP002071710 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9528088B2 (en) 2002-06-28 2016-12-27 Life Technologies Corporation Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation

Also Published As

Publication number Publication date
AU5590198A (en) 1998-06-03
WO1998021314A2 (en) 1998-05-22

Similar Documents

Publication Publication Date Title
WO1998055495A3 (en) Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
CA2105552A1 (en) Soluble ligands for cd40
CA2193337A1 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
NZ333607A (en) Method of stimulating the immune system by transfecting dendritic cells
EP0921816A4 (en) Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
CA2295604A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
EP2213302A3 (en) DR4 antibodies and uses thereof
WO2003045427A3 (en) Pharmaceutical composition for inducing an immune response in a human or animal
TR199800607T1 (en) Dendritic h�cre uyar�c� fact�r�.
WO1998008542A3 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
NZ322910A (en) Tumour vaccine containing tumour cells, some with MHC-I-haplotype on cell surface to trigger immune response, and preparation of vaccine thereof
CA2262001A1 (en) Mhc binding peptide oligomers and methods of use
CA2232344A1 (en) Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
CA2295321A1 (en) Isolated nona- and decapeptides which bind to hla molecules, and the use thereof
WO1997005899A3 (en) Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
CA2250880A1 (en) Implantable agarose-collagen beads containing cells which produce a diffusible biological product, and uses thereof
WO1998021314A3 (en) Method of promoting B-cell proliferation and activation and of modulating the immune system
NZ331398A (en) Tumor rejection antigens presented by hla-b44 molecules, and uses thereof
CA2157500A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation
EP1211311A3 (en) Cord blood-derived activated lymphocytes and preparations containing said lymphocytes
AU7520398A (en) Test kit for tuberculosis diagnosis or the like
CA2262546A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
IL110585A0 (en) Tripeptides, their preparation and pharmaceutical compositions containing them
CA2273848A1 (en) Mycobacterium vaccae for down-regulation of the th2 activity of the immune system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA